Corpus ID: 418538

[Efficacy and safety of sitafloxacin in patients with urinary tract infections].

@article{Matsumoto2012EfficacyAS,
  title={[Efficacy and safety of sitafloxacin in patients with urinary tract infections].},
  author={Takuyuki Matsumoto and Hiroki Yamaguchi and Kazuhiro Uchino and Megumi Takahashi and Hiroko Kodama and Satoko Hamajima and Rie Yonemochi and Sachiko Fujita and Atsushi Takita and Naoki Yamanouchi and Tomoo Shiozawa and Yukihiro Okutani},
  journal={The Japanese journal of antibiotics},
  year={2012},
  volume={65 6},
  pages={
          365-80
        }
}
Sitafloxacin (STFX, Gracevit 50mg, fine granules 10%), a new quinolone antibacterial agent, was approved in January 2008, and the use-results survey was carried out over the 2 years between December 2008 and November 2010. We studied the efficacy and safety of STFX in 1,452 patients with urinary tract infections (cystitis, pyelonephritis, urethritis). The total efficacy rate for urinary tract infections was 91.4% (1,235/1,351 patients). Efficacy rates, classified by the type of infection, were… Expand
Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis
TLDR
These results support the use of oral sitafloxacin in complicated urinary tract infections and acute pyelonephritis, however, further larger studies are required to confirm these results. Expand